Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Lee

Sports Medicine Nyc, NY Medical Doctor

NPI 1538154380 CMS profile 115295

130 E 77Th St, 5Th Floor, Nyc, NY 10021

Open in the dashboard

General payments

$3,263,905

833 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Lee of Nyc, NY is reported in the CMS Open Payments database as having received $3,263,905 across 833 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $554,983 118
2024 General $546,358 123
2023 General $529,377 74
2022 General $492,200 142
2021 General $441,644 112
2020 General $372,858 99
2019 General $326,485 165

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Lee
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Steven Lee were reported at $554,983. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Steven Lee Sports Medicine median Middle half National median
2019 $326,485 $1,176 $199–$4,249 $163
2020 $372,858 $708 $96–$2,890 $114
2021 $441,644 $1,213 $152–$3,994 $132
2022 $492,200 $1,230 $159–$3,998 $149
2023 $529,377 $584 $146–$2,836 $160
2024 $546,358 $628 $163–$3,168 $164
2025 $554,983 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $3,244,082 697 payments
  2. Gotham Surgical Solutions & Devices, Inc. $6,077 16 payments
  3. Sanara MedTech Inc. $1,817 11 payments
  4. Stryker Corporation $1,539 12 payments
  5. Djo, LLC $1,510 10 payments
  6. PolyNovo North America LLC $1,328 9 payments
  7. Suvon Surgical LLC $1,296 10 payments
  8. Globus Medical, Inc. $943 8 payments
  9. Acumed LLC $656 8 payments
  10. AxoGen $521 6 payments
  11. Other $4,135 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $2,302,398 28 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $651,966 103 payments
  3. Consulting Fee $225,627 89 payments
  4. Travel and Lodging $57,541 225 payments
  5. Food and Beverage $21,649 384 payments
  6. Education $4,724 4 payments
Products named General payments · program years 2019–2025
  1. Arthrex Upper Extremity - Implants - Hand & Wrist - IB Ligament Augmentation - Knotless $693,227 6 payments
  2. ARTHREX Distal Extremities - Implants - Soft Tissue - Anchors $688,550 8 payments
  3. ARTHREX Distal Extremities - Instruments - Soft Tissue - Disposable Kits $688,550 8 payments
  4. ARTHREX Distal Extremities - Implants - Soft Tissue - Anchors $688,550 8 payments
  5. ARTHREX Distal Extremities - Implants - Soft Tissue - Anchors $688,550 8 payments
  6. Arthrex Upper Extremity - Implants - Hand & Wrist - Corkscrews $427,491 4 payments
  7. Arthrex Upper Extremity - Instruments - Hand & Wrist - SwiveLocks $427,491 4 payments
  8. Arthrex Upper Extremity - Implants - Hand & Wrist - IB Ligament Augmentation $427,491 4 payments
  9. Arthrex Upper Extremity - Implants - Hand & Wrist - CMC $427,491 4 payments
  10. Arthrex Upper Extremity - Implants - Hand & Wrist - IB Ligament Augmentation $427,491 4 payments
  11. Other $4,994,563 222 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

164

Median for Orthopedic Surgery: 203

Drug cost

$956

Median for Orthopedic Surgery: $1,433

Branded share of claims

63.4%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 89 $655
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 15 $114
Tramadol Hcl Generic 31 $102
Meloxicam Generic 29 $84

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 140 billing codes

Paid by Medicare

$231,376

Of which drugs: $7,140

Medicare patients

562

Average age 76

Services billed

4,787

364 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 71%
High blood pressure 63%
Osteoporosis 27%
Diabetes 24%
Ischemic heart disease 24%
Cancer 20%
Depression 20%
Atrial fibrillation 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg J7331 Office 11 671 $5,373
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 114 863 $75
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 27 $21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

833 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record